Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta‐analysis
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background and Aims: There are a limited number of pharmacotherapies licensed for alcohol use disorders (AUDs). Baclofen is a γ‐aminobutyric acid B (GABA‐B) agonist which is used increasingly as an off‐label treatment. A meta‐analysis of randomized controlled trials (RCTs) was conducted to determine the efficacy of baclofen in reducing drinking behaviour, craving, depression and anxiety compared with placebo. Methods: Random‐effects meta‐analyses were computed on outcome data from 12 RCTs comparing baclofen with placebo. Included RCTs provided data on at least one of the primary outcome measures (drinking‐related: heavy drinking days, abstinent days, abstinence rates) or secondary outcome measures (craving, anxiety, depression). Results: Baclofen had a significant effect on abstinence rates when using intention‐to‐treat analysis [total n baclofen = 307, total n control = 283: odds ratio (OR) = 2.67, 95% confidence interval (CI) = 1.03, 6.93; Z = 2.01, P = 0.04, I 2 = 76%, number needed to treat = 8]. No other significant effects of treatment efficacy [e.g. heavy drinking days: standardized mean differences (SMD) = −0.26, 95% CI = –0.68, 0.15; Z = 1.24, P = 0.21, I 2 = 95%] or mechanism of action (e.g. craving: SMD = −0.13, 95% CI = −0.36, 0.09; Z = 1.18, P = 0.24, I 2 = 87%) were observed. There was substantial heterogeneity in effect sizes across each analysis. Conclusions: As a treatment for alcohol use disorders, baclofen is associated with higher rates of abstinence than placebo. However, there is no superior effect of baclofen on increasing number of abstinent days, or decreasing heavy drinking, craving, anxiety or depression. These results suggest that the current increasing use of baclofen as a treatment for alcohol use disorders is premature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intention-to-treat concept: A review
Gupta, S. (2011) · Perspectives in Clinical Research · doi:10.4103/2229-3485.83221 · Cited by 1,921
Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087366 · Cited by 347
Randomized open-label trial of baclofen for relapse prevention in alcohol dependence
Gupta, M., Verma, P., Rastogi, R., Arora, S., & Elwadhi, D. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1240797 · Cited by 26
Cited by
Ultrasound‐Activated Sensitizers and Applications
Lin, X., Song, J., Chen, X., & Yang, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201906823 · Cited by 501
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“A recent meta-analysis of 12 RCTs (N = 703) showed that baclofen in comparison to placebo was associated with higher abstinence rates [81–83]; however, it did not increase abstinent days or decrease craving, heavy drinking, depression, or anxiety [84].”
BackgroundThe Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
de Beaurepaire, R., Sinclair, J. M. A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., Chick, J. D., de La Selle, P., Franchitto, N., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00708 · Cited by 95
Baclofen for alcohol use disorder
Minozzi, S., Saulle, R., & Rösner, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub2 · Cited by 73
Garbutt, J. C., Kampov-Polevoy, A. B., Pedersen, C., Stansbury, M., Jordan, R., Willing, L., & Gallop, R. J. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01055-w · Cited by 68
Metadata
- Authors
- Rose, A. K., & Jones, A.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2018-03-24
- Volume
- 113
- Issue
- 8
- Pages
- 1396-1406
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2793489992
- Cited by
- 137
- References
- 3
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.